Pandemrix
Sign in to savePandemrix is an influenza vaccine for influenza pandemics, such as the 2009 flu pandemic. The vaccine was developed by GlaxoSmithKline (GSK) and patented in September 2006.
In the Vinony graph
Vinony's link graph records 540 inbound references to Pandemrix, and connects out to influenza, influenza vaccine and meningococcal vaccine.
It is catalogued under topics including 2009 swine flu pandemic, Chemical pages without DrugBank identifier and Chemicals that do not have a ChemSpider ID assigned.
Vinony links it to 11 Wikipedia language editions.
~13 min read
Encyclopedic overview
11 sectionsContents
- Constituents
- Use of adjuvant
- Dosage
- Availability
- Clinical trials
- Side effects
- Adverse outcomes
- Narcolepsy
- See also
- References
- External links
Pandemrix is an influenza vaccine for influenza pandemics, such as the 2009 flu pandemic. The vaccine was developed by GlaxoSmithKline (GSK) and patented in September 2006.
The vaccine was one of the H1N1 vaccines approved for use by the European Commission in September 2009, upon the recommendations of the European Medicines Agency (EMEA). The vaccine is only approved for use when an H1N1 influenza pandemic has been officially declared by the World Health Organization (WHO) or European Union (EU). The vaccine was initially developed as a pandemic mock-up vaccine using an H5N1 strain.
Excerpted from Wikipedia’s “Pandemrix” article, available under the CC BY-SA 4.0 licence.